Macrophage-Mediated Antibody Dependent Effector Function in Aggressive B-Cell Lymphoma Treatment is Enhanced by Ibrutinib via Inhibition of JAK2. The gene discussed is JAK2; the disease is B-cell non-Hodgkin lymphoma.